What type of study is this?

This is a Human Clinical Trial study.

December 8, 2025BloodOpen Access

A Phase 1/2 study of the menin inhibitor revumenib with the celmod mezigdomide in relapsed/refractory KMT2A-rearanged, NPM1-mutant, and NUP98-rearranged acute leukemias

View Full Paper

Ask AI

Bookmark

Authors

Phase 1/2 trial shows promise for revumenib and mezigdomide in relapsed/refractory acute leukemias, indicating improved treatment options.

Phase 1/2 trial evaluates safety and tolerability of revumenib combined with mezigdomide in acute leukemias.
Maximum tolerated dose will be determined in participants with KMT2Ar, NPM1c, or NUP98r alterations.
Dexamethasone is used in conjunction with mezigdomide for optimal treatment efficacy in acute leukemias.
Findings aim to enhance therapeutic options for acute leukemias resistant to existing treatment.

Chin et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase 1/2 trial shows promise for revumenib and mezigdomide in relapsed/refractory acute leukemias, indicating improved treatment options.